Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Li Auto Inc (LI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Li Auto Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Li Auto Inc trades at $12.18 (market cap $11.78B). The key difference: Li Auto Inc is far larger — about 2.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | LI | |
|---|---|---|
Market Cap | $4.49B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $31.80 |
52-Week Low | $20.06 | $11.74 |
Enterprise Value | $3.69B | $693.65M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Li Auto (LI) trades at $12.05, near its 52-week low, with a bearish technical outlook. Revenue declined to $112.31B in 2025, and net income fell to $1.12B, reflecting margin pressure. Analyst consensus is mixed with a $14.80 price target, but recent news highlights competitive headwinds and delivery growth of 30,895 vehicles in June 2026.
The stock faces near-term risks from intense EV competition and profitability challenges, but long-term recovery potential exists if L-series execution improves. Investors should weigh low valuation multiples against operational cash flow deficits and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
